Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

UCLA Oncologist Pursues Promise of CSF1R Inhibitor Combos

April 9th 2018

Zev A. Wainberg, MD, discusses data from the pancreatic cancer cohort of a trial evaluating cabiralizumab in combination with nivolumab.

Ramucirumab Improves Survival in Second-Line HCC

April 4th 2018

Ramucirumab extended overall survival versus placebo as a second-line treatment for patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein, according to findings from the phase III REACH-2 trial.

Dr. Helft Discusses Pancreatic and Carcinoid NETs

April 3rd 2018

Paul R. Helft, MD, professor of medicine, Indiana University School of Medicine, Indiana University Health Melvin and Bren Simon Cancer Center, discusses pancreatic and carcinoid neuroendocrine tumors.

Dr. Bekaii-Saab Discusses the Next Steps With Regorafenib in CRC

April 3rd 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the next steps following for regorafenib (Stivarga) in colorectal cancer (CRC).

Bekaii-Saab Highlights Emerging Agents in Pancreatic Cancer Pipeline

March 30th 2018

Tanios Bekaii-Saab, MD, discusses emerging treatments offering hope to patients with pancreatic cancer.

Precision Medicine Impact Grows in GI Cancer Paradigm

March 30th 2018

Bert H. O’Neil, MD, discusses the role of molecular testing throughout GI cancers and highlights the current and developing treatment landscape for patients with colorectal cancer.

Immunotherapy Arrives in Gastric Cancer

March 30th 2018

Manish A. Shah, MD, discusses the advancements being made in the treatment of patients with advanced gastric and gastroesophageal junction cancer.

Dr. Janjigian on Immunotherapy Combinations in Gastric Cancer

March 29th 2018

Yelena Y. Janjigian, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the addition of checkpoint inhibitors to the treatment landscape for patients with gastric and esophageal cancer, as well as potential combinations being investigated.

Expert Sheds Light on Recent Advances in mCRC

March 29th 2018

Shubham Pant, MD, shares his insight on the future direction of the treatment landscape of colorectal cancer.

Dr. O'Neil Discusses the Current Treatment of Patients With CRC

March 28th 2018

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the current treatment of patients with colorectal cancer.

Dr. Pant on the Future of mCRC Treatment

March 28th 2018

Shubham Pant, MD, associate medical director of the Clinical & Translational Research Center, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing efforts in metastatic colorectal cancer (mCRC) and his hope for the future treatment landscape.

Trastuzumab Deruxtecan Receives Expedited Review in Japan for Gastric Cancer

March 28th 2018

Japanese regulators have granted a Sakigake designation to trastuzumab deruxtecan (DS-8201), for the treatment of patients with HER2-positive gastric cancer that is refractory to trastuzumab (Herceptin).

Dr. Svensson on the Impact of PD-L1 Status in Gastric and Esophageal Adenocarcinoma

March 27th 2018

Maria Svensson, MD, Lund University, discusses the impact of determining PD-1 and PD-L1 status for patients with esophageal and gastric adenocarcinoma.

FDA Grants Nivolumab/Ipilimumab Priority Review for MSI-H/dMMR Colorectal Cancer

March 27th 2018

The FDA has granted a priority review to a supplemental biologics license application for nivolumab plus ipilimumab for the treatment of adult patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Dr. O'Reilly Discusses Biomarker Research in Pancreatic Cancer

March 23rd 2018

Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center discusses biomarker research in pancreatic cancer.

Immunotherapy, Sidedness Strategies Enhancing mCRC Treatment

March 23rd 2018

Chloe E. Atreya, MD, PhD, discusses the latest treatment advances in mCRC, including tumor sidedness and emerging immunotherapy strategies.

Lenvatinib Approved for HCC in Japan

March 23rd 2018

Japan’s Pharmaceuticals and Medical Devices Agency has approved lenvatinib mesylate for the frontline treatment of patients with unresectable hepatocellular carcinoma.

Expert Highlights Precision Medicine Advances in GI Cancers

March 21st 2018

Eric A. Collisson, MD, discusses ongoing efforts to advance precision medicine in GI malignancies to improve the standard of care.

Dr. Van Loon on the PROSPECT Trial

March 21st 2018

Katherine Van Loon, MD, gastrointestinal cancer specialist, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the design of the multicenter PROSPECT trial.

Novel Therapies Bring Hope in Biliary Tract Cancers

March 21st 2018

John Gordan, MD, PhD, discusses the challenges of treating patients with biliary tract cancers and novel therapies in development.

NEXT PAGE
PREVIOUS PAGE